Sharda Cropchem Ltd (SHARDACROP) — share price & stock analysis
Profits have nearly tripled in two years, the price has kept pace — no more, no less.
Sharda Cropchem Ltd (SHARDACROP) trades at ₹885 as of 1 July 2026, down 3.6% over the past year — trailing NIFTY 500 for 5 weeks. The machine reads this as steady growth, fairly priced: profits have nearly tripled in two years, the price has kept pace — no more, no less. It trades at a P/E of 11.7× (the 50th percentile of its own range); the price is in Stage 2 — advancing, 57 weeks in; the business cycle reads DEEP CYCLICAL / EXPANSION. Fundamentals-momentum score: 89/100 (mostly improving).
Data as of 1 July 2026 · every number traces to its Screener source column · not investment advice.
- Market cap
- ₹7,984 Cr
- P/E
- 11.7×
- ROE
- 24.2%
- vs own 10-yr valuation
- 50th pctile
- Book value / share
- ₹348
- EPS (TTM)
- ₹75.6
- 10-yr median P/E
- 17.2×
- Revenue (FY26)
- ₹5,268 Cr
- Profit after tax (FY26)
- ₹681 Cr
- Weinstein stage
- Stage 2 (57 weeks)
- Data as of
- 1 July 2026
Profits swing violently in this business — a 91% peak-to-trough profit collapse. That is what “deep cyclical” means: the same company looks brilliant at the top of its cycle and broken at the bottom.net_profit
Where the clock stands now: earnings sit at 100% of their historical range, margins are near the top of their band, and the market pays mid-range (50th percentile). That reads as EXPANSION — the comfortable middle — but the records are already on the table; from here the bet is that they keep coming.net_profit
5 of the 6 things we track are currently moving the right way — nearly everything is pulling in the same direction.
Where the levels actually stand: ROCE 30% — a high-quality engine; effectively no debt; margins near the top of their band. Momentum says which way things are moving; these say where they are.
Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double.
Price and profits are moving together
Since Mar 2016, the stock is up 269% and earnings per share are up 289% — the price has tracked the profits, not run ahead of them.pricettm_eps
The market is paying for delivery, not promises. What you see in earnings is what you get in the price.
Today’s P/E of 11.7× is the middle of its own range against its own 10-year history (50th percentile) — neither a bargain nor a stretch, by its own standards.pe_ratio
Data: Price, EPS and valuation (sampled — full series in the embedded dataset)
| Period | Price (₹) | EPS (TTM) (₹) | P/E (×) |
|---|---|---|---|
| Mar 16 | 224 | – | 16.4 |
| Jun 16 | 375 | 19.5 | 19.3 |
| Aug 16 | 360 | 19.9 | 18.1 |
| Oct 16 | 422 | 20.7 | 20.4 |
| Dec 16 | 444 | 19.7 | 21.5 |
| Mar 17 | 469 | 21.2 | 22.1 |
| May 17 | 552 | 21.1 | 25.9 |
| Jul 17 | 483 | 21.4 | 22.9 |
| Oct 17 | 454 | 21.4 | 21.2 |
| Dec 17 | 461 | 20.4 | 22.6 |
| Feb 18 | 396 | 19.5 | 20.3 |
| May 18 | 396 | 19.5 | 20.3 |
| Jul 18 | 344 | 21.1 | 16.3 |
| Sep 18 | 344 | 20.1 | 17.1 |
| Nov 18 | 297 | 19.3 | 15.4 |
| Feb 19 | 321 | 20.5 | 15.7 |
| Apr 19 | 388 | 20.4 | 19.0 |
| Jun 19 | 314 | 19.5 | 16.1 |
| Sep 19 | 284 | 18.3 | 15.5 |
| Nov 19 | 256 | 15.9 | 16.1 |
| Jan 20 | 256 | 14.3 | 18.0 |
| Apr 20 | 105 | 14.2 | 7.4 |
| Jun 20 | 175 | – | 12.3 |
| Aug 20 | 309 | 18.9 | 16.4 |
| Oct 20 | 273 | 21.6 | 12.7 |
| Jan 21 | 276 | 21.6 | 12.8 |
| Mar 21 | 310 | 26.2 | 11.8 |
| May 21 | 343 | 25.4 | 13.5 |
| Aug 21 | 331 | 26.5 | 12.5 |
| Oct 21 | 319 | 26.6 | 12.0 |
| Dec 21 | 340 | 28.1 | 12.1 |
| Mar 22 | 546 | 33.9 | 16.1 |
| May 22 | 646 | 38.7 | 16.7 |
| Jul 22 | 693 | 37.0 | 18.0 |
| Sep 22 | 443 | 36.9 | 12.0 |
| Dec 22 | 482 | 34.9 | 13.8 |
| Feb 23 | 478 | 35.4 | 13.5 |
| Apr 23 | 464 | 35.4 | 13.1 |
| Jul 23 | 540 | – | 14.8 |
| Sep 23 | 439 | 25.6 | 17.2 |
| Nov 23 | 415 | – | 19.6 |
| Feb 24 | 384 | 9.7 | 39.7 |
| Apr 24 | 378 | – | 39.1 |
| Jun 24 | 446 | – | – |
| Aug 24 | 563 | 16.4 | 34.4 |
| Nov 24 | 815 | 24.1 | 33.8 |
| Jan 25 | 728 | 24.1 | 30.2 |
| Mar 25 | 572 | 27.1 | 21.1 |
| Jun 25 | 780 | 33.8 | 23.1 |
| Aug 25 | 957 | – | 20.6 |
| Oct 25 | 890 | 46.6 | 19.1 |
| Jan 26 | 855 | 50.0 | 17.1 |
| Feb 26 | 1,191 | 62.7 | 19.0 |
| May 26 | 1,122 | 62.7 | 17.9 |
| Jun 26 | 888 | 75.3 | 11.8 |
| Jul 26 | 885 | 75.6 | 11.7 |
Price is the weekly close (₹). EPS is trailing-twelve-month profit per share, anchored on Screener's own snapshots; between snapshots it is filled from price ÷ P/E (an exact identity), and any fill straying more than 18% from the neighbouring snapshots is dropped rather than shown. The lower panel is the P/E — what the market pays per rupee of profit; the dotted line is its long-run median (17.2×).
The price is in a confirmed uptrend — 57 weeks and counting
STAGE 2 · ADVANCING · 57 WEEKSStock prices move through four repeating stages: basing (1), advancing (2), topping (3) and declining (4). This one is in Stage 2: advancing, 57 weeks in, confirmed.stage
The price sits above its rising 200-day average (₹935 today) — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200
Trailing NIFTY 500 for 5 weeks — relative strength is the market’s live opinion, and right now it is against it.rs_mansfield
What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200
Data: Weekly price, moving averages and stage (sampled — full series in the embedded dataset)
| Period | Price (₹) | 200-DMA (₹) | 50-DMA (₹) | Stage |
|---|---|---|---|---|
| Feb 16 | 208 | 262 | 229 | 4 |
| May 16 | 289 | 260 | 263 | 4 |
| Aug 16 | 360 | 310 | 365 | 2 |
| Nov 16 | 406 | 347 | 402 | 2 |
| Jan 17 | 476 | 389 | 451 | 2 |
| Apr 17 | 518 | 428 | 479 | 2 |
| Jul 17 | 483 | 460 | 494 | 2 |
| Oct 17 | 454 | 456 | 452 | 4 |
| Dec 17 | 450 | 456 | 457 | 1 |
| Mar 18 | 369 | 436 | 403 | 4 |
| Jun 18 | 395 | 423 | 408 | 4 |
| Sep 18 | 396 | 401 | 384 | 4 |
| Nov 18 | 297 | 370 | 326 | 4 |
| Feb 19 | 352 | 343 | 318 | 4 |
| May 19 | 344 | 357 | 371 | 2 |
| Aug 19 | 306 | 339 | 311 | 4 |
| Nov 19 | 276 | 317 | 288 | 4 |
| Jan 20 | 256 | 285 | 254 | 4 |
| Apr 20 | 148 | 239 | 168 | 4 |
| Jul 20 | 275 | 216 | 206 | 4 |
| Oct 20 | 261 | 246 | 270 | 2 |
| Dec 20 | 270 | 256 | 271 | 2 |
| Mar 21 | 310 | 276 | 306 | 2 |
| Jun 21 | 375 | 296 | 332 | 2 |
| Sep 21 | 305 | 313 | 327 | 2 |
| Nov 21 | 314 | 317 | 321 | 3 |
| Feb 22 | 561 | 369 | 469 | 2 |
| May 22 | 646 | 470 | 607 | 2 |
| Aug 22 | 527 | 547 | 615 | 2 |
| Oct 22 | 389 | 515 | 474 | 4 |
| Jan 23 | 480 | 488 | 469 | 4 |
| Apr 23 | 462 | 481 | 469 | 4 |
| Jul 23 | 540 | 495 | 522 | 2 |
| Sep 23 | 420 | 475 | 450 | 4 |
| Dec 23 | 431 | 452 | 425 | 4 |
| Mar 24 | 331 | 424 | 378 | 4 |
| Jun 24 | 411 | 404 | 384 | 4 |
| Aug 24 | 563 | 456 | 528 | 2 |
| Nov 24 | 805 | 540 | 675 | 2 |
| Feb 25 | 536 | 615 | 660 | 2 |
| May 25 | 525 | 586 | 559 | 4 |
| Aug 25 | 1,107 | 694 | 853 | 2 |
| Oct 25 | 890 | 780 | 866 | 2 |
| Jan 26 | 824 | 809 | 850 | 2 |
| Apr 26 | 1,057 | 907 | 1,002 | 2 |
| Jun 26 | 914 | 939 | 971 | 2 |
| Jul 26 | 885 | 935 | 946 | 2 |
Profits are at an all-time high
Over 12 years, sales went from ₹790 Cr to ₹5,268 Cr (about 17% a year), and profit from ₹111 Cr to ₹681 Cr.revenuenet_profit
Margins took a round trip — down to 9.6% in FY24, back to 20.4% now. The profit growth survived the squeeze.operating_profit
Data: Revenue by year
| Period | Revenue (₹ Cr) |
|---|---|
| FY14 | 790 |
| FY15 | 1,061 |
| FY16 | 1,222 |
| FY17 | 1,399 |
| FY18 | 1,707 |
| FY19 | 1,998 |
| FY20 | 2,003 |
| FY21 | 2,396 |
| FY22 | 3,580 |
| FY23 | 4,045 |
| FY24 | 3,163 |
| FY25 | 4,320 |
| FY26 | 5,268 |
Data: Profit by year
| Period | Profit after tax (₹ Cr) |
|---|---|
| FY14 | 111 |
| FY15 | 123 |
| FY16 | 175 |
| FY17 | 190 |
| FY18 | 191 |
| FY19 | 176 |
| FY20 | 165 |
| FY21 | 229 |
| FY22 | 349 |
| FY23 | 342 |
| FY24 | 32 |
| FY25 | 304 |
| FY26 | 681 |
Data: OPM % by year
| Period | OPM % (%) |
|---|---|
| FY14 | 20.3 |
| FY15 | 17.2 |
| FY16 | 23.0 |
| FY17 | 23.2 |
| FY18 | 21.3 |
| FY19 | 18.8 |
| FY20 | 17.5 |
| FY21 | 18.8 |
| FY22 | 19.4 |
| FY23 | 16.3 |
| FY24 | 9.6 |
| FY25 | 14.2 |
| FY26 | 20.4 |
Sales grew 13% last quarter — growth every single quarter for over 2 years
Mar 26 sales were ₹2,065 Cr, up 13% on the same quarter last year.revenue
That makes 8 quarters of growth in a row — this is a trend, not a blip.revenue
Data: Quarterly sales
| Period | Revenue (₹ Cr) | YoY growth (%) |
|---|---|---|
| Jun 23 | 638 | – |
| Sep 23 | 581 | – |
| Dec 23 | 632 | – |
| Mar 24 | 1,312 | – |
| Jun 24 | 785 | 23.0 |
| Sep 24 | 777 | 33.7 |
| Dec 24 | 929 | 47.0 |
| Mar 25 | 1,829 | 39.4 |
| Jun 25 | 985 | 25.5 |
| Sep 25 | 929 | 19.6 |
| Dec 25 | 1,289 | 38.8 |
| Mar 26 | 2,065 | 12.9 |
Margins are widening — 17% → 24% in a year
Of every ₹100 of sales, the company keeps ₹23.6 as operating profit (a year ago it kept ₹16.6).opm_pct
Zoom out and this is the page's quiet hero: annual operating margin bottomed at 9.6% in FY24 and has been rebuilt to 20.4% — that recovery, not sales alone, is what powers the profit growth elsewhere on this page.operating_profit
The gross margin moved the same way (30% → 37%), so this is about input costs and pricing power — the raw-material equation improved.gpm_pctopm_pct
Data: Three margins, quarterly
| Period | Gross (%) | Operating (%) | Net (%) |
|---|---|---|---|
| Jun 23 | 8.7 | -9.3 | -13.9 |
| Sep 23 | 25.1 | 3.7 | -4.8 |
| Dec 23 | 26.2 | 11.0 | 0.7 |
| Mar 24 | 34.6 | 19.4 | 10.9 |
| Jun 24 | 29.2 | 9.8 | 3.5 |
| Sep 24 | 27.6 | 11.5 | 5.5 |
| Dec 24 | 32.7 | 12.3 | 3.4 |
| Mar 25 | 29.8 | 16.6 | 11.1 |
| Jun 25 | 35.5 | 21.9 | 14.5 |
| Sep 25 | 34.5 | 14.3 | 8.0 |
| Dec 25 | 34.9 | 18.7 | 11.3 |
| Mar 26 | 37.3 | 23.6 | 15.4 |
Profit exploded 56% — mostly from keeping more of each sale
Mar 26 profit after tax was ₹319 Cr, up 56% year on year.net_profit
Data: Quarterly profit after tax
| Period | PAT (₹ Cr) | YoY growth (%) |
|---|---|---|
| Jun 23 | -89.0 | – |
| Sep 23 | -28.0 | – |
| Dec 23 | 5.0 | – |
| Mar 24 | 143 | – |
| Jun 24 | 27.0 | 130.3 |
| Sep 24 | 42.0 | 250.0 |
| Dec 24 | 31.0 | 520.0 |
| Mar 25 | 204 | 42.7 |
| Jun 25 | 143 | 429.6 |
| Sep 25 | 74.0 | 76.2 |
| Dec 25 | 145 | 367.7 |
| Mar 26 | 319 | 56.4 |
The single biggest driver was keeping more of each sale.
Data: Where the profit change came from (Mar 25 → Mar 26)
| Component | Effect (₹ Cr) |
|---|---|
| PAT Mar 25 | 204 |
| More sales | +39 |
| Fatter margins | +145 |
| Other income | −3 |
| Depreciation | −15 |
| Tax | −51 |
| PAT Mar 26 | 319 |
The profits are real — they turn into cash
Over the last 5 profitable years, the business reported ₹1,708 Cr of profit and collected ₹2,196 Cr of operating cash — about 129% conversion.operating_cash_flownet_profit
When cash tracks profit this closely, the earnings need no asterisk.
Data: Cash collected vs profit reported (annual)
| Period | Operating cash flow (₹ Cr) | Profit after tax (₹ Cr) |
|---|---|---|
| FY14 | 156 | 111 |
| FY15 | 46.0 | 123 |
| FY16 | 197 | 175 |
| FY17 | 181 | 190 |
| FY18 | 17.0 | 191 |
| FY19 | 556 | 176 |
| FY20 | 146 | 165 |
| FY21 | 246 | 229 |
| FY22 | 267 | 349 |
| FY23 | 328 | 342 |
| FY24 | 341 | 32.0 |
| FY25 | 604 | 304 |
| FY26 | 656 | 681 |
The cash cycle is stable
One rupee now takes about 125 days to go out the door as materials and come back as collected cash.cash_conversion_cycle
Data: Days of cash locked up (annual)
| Period | Customers owe (debtor days) (days) | Stock on shelf (inventory days) (days) | We owe suppliers (payable days) (days) |
|---|---|---|---|
| FY14 | 185 | 57.0 | 146 |
| FY15 | 156 | 72.0 | 117 |
| FY16 | 185 | 74.0 | 179 |
| FY17 | 175 | 117 | 186 |
| FY18 | 191 | 169 | 202 |
| FY19 | 148 | 96.0 | 167 |
| FY20 | 180 | 100 | 180 |
| FY21 | 177 | 117 | 180 |
| FY22 | 157 | 130 | 172 |
| FY23 | 165 | 145 | 176 |
| FY24 | 173 | 155 | 144 |
| FY25 | 165 | 117 | 158 |
| FY26 | 166 | 121 | 162 |
The asset base keeps compounding — this company builds
The productive asset base has gone from ₹64.0 Cr (FY14) to ₹1,236 Cr.fixed_assetscwip
The build is self-funded: the last 3 years' investing outflow (₹1,402 Cr) fits inside the operating cash the business generated (₹1,601 Cr).investing_cash_flowoperating_cash_flow
Data: Assets in place vs under construction (annual)
| Period | Fixed assets (₹ Cr) | Under construction (CWIP) (₹ Cr) |
|---|---|---|
| FY14 | 64.0 | 133 |
| FY15 | 88.0 | 149 |
| FY16 | 130 | 210 |
| FY17 | 210 | 232 |
| FY18 | 226 | 360 |
| FY19 | 372 | 220 |
| FY20 | 416 | 161 |
| FY21 | 544 | 131 |
| FY22 | 592 | 212 |
| FY23 | 668 | 204 |
| FY24 | 708 | 283 |
| FY25 | 750 | 291 |
| FY26 | 1,236 | 0.0 |
Almost no debt — this company cannot be killed by a bad year
For every ₹100 shareholders have put in (and left in), the company has borrowed ₹0 — total borrowings have shrunk from ₹40.0 Cr to ₹0.0 Cr over the window.borrowings
Data: Total borrowings (annual)
| Period | Borrowings (₹ Cr) |
|---|---|
| FY14 | 40.0 |
| FY15 | 38.0 |
| FY16 | 2.0 |
| FY17 | 0.0 |
| FY18 | 170 |
| FY19 | 0.0 |
| FY20 | 0.0 |
| FY21 | 81.0 |
| FY22 | 47.0 |
| FY23 | 3.0 |
| FY24 | 18.0 |
| FY25 | 8.0 |
| FY26 | 0.0 |
Data: Debt vs shareholders’ money (annual)
| Period | Debt ÷ equity (x) |
|---|---|
| FY14 | 0.1 |
| FY15 | 0.1 |
| FY16 | 0.0 |
| FY17 | 0.0 |
| FY18 | 0.2 |
| FY19 | 0.0 |
| FY20 | 0.0 |
| FY21 | 0.1 |
| FY22 | 0.0 |
| FY23 | 0.0 |
| FY24 | 0.0 |
| FY25 | 0.0 |
| FY26 | 0.0 |
Every ₹100 kept in the business now earns ₹30 — and the number is rising
Return on capital employed is 30.0% (a year ago: 16.0%). This is the single best test of business quality: what the company earns on the money it keeps.roce_pct
Rising returns on capital while growing is the rarest combination in investing — it means the new projects earn more than the old ones.roce_pct
Data: Returns on capital (annual)
| Period | ROCE (%) |
|---|---|
| FY14 | 28.0 |
| FY15 | 27.0 |
| FY16 | 36.0 |
| FY17 | 32.0 |
| FY18 | 27.0 |
| FY19 | 23.0 |
| FY20 | 18.0 |
| FY21 | 21.0 |
| FY22 | 26.0 |
| FY23 | 21.0 |
| FY24 | 4.0 |
| FY25 | 16.0 |
| FY26 | 30.0 |
The owners aren’t moving
Promoters hold 74.8%, essentially unchanged. Foreign funds own 4.6%, domestic funds 9.7%.promoters_pctfiis_pctdiis_pct
Institutions buying while the story develops is the market’s quiet vote of confidence — they meet management, you don’t.
Meanwhile domestic funds have been the sellers — from 12.8% to 9.7% over the window. Someone on the other side of the table disagrees; both sides count.diis_pct
Data: Who holds the shares, quarterly
| Period | Promoters (%) | Foreign funds (%) | Domestic funds (%) |
|---|---|---|---|
| Jun 23 | 74.8 | 2.0 | 12.8 |
| Sep 23 | 74.8 | 2.0 | 12.3 |
| Dec 23 | 74.8 | 2.1 | 12.4 |
| Mar 24 | 74.8 | 2.1 | 12.4 |
| Jun 24 | 74.8 | 2.0 | 12.9 |
| Sep 24 | 74.8 | 2.5 | 12.8 |
| Dec 24 | 74.8 | 3.8 | 10.1 |
| Mar 25 | 74.8 | 4.7 | 10.3 |
| Jun 25 | 74.8 | 5.5 | 9.4 |
| Sep 25 | 74.8 | 5.3 | 9.3 |
| Dec 25 | 74.8 | 4.2 | 10.0 |
| Mar 26 | 74.8 | 4.6 | 9.7 |
- Promoters are not selling. Their stake has moved 0.1 points or less in 8 quarters — it sits at 74.8%.promoters_pct
Worth studying deeper — with eyes open
The numbers lean positive, and the price is roughly fair to the delivery so far.
Best thing in the data: returns on capital rising (16.0% → 30.0%).roce_pct
One dissent worth hearing: our technicals lens reads negative — “Technicals bearish with 57% confidence”. When a lens disagrees with the committee, it is usually pointing at the thing that breaks first.
Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.
Straight answers from the data
What does Sharda Cropchem Ltd do?
Sharda Cropchem is principally engaged in export of agrochemicals (technical grade and formulations) and non-agro products such as conveyor belts, rubber belts/sheets, dyes and dye intermediates to various countries across the world. It is listed in the Pesticides/Agrochemicals sector with a market capitalisation of ₹7,984 Cr.
What is Sharda Cropchem Ltd's share price?
As of 1 July 2026, Sharda Cropchem Ltd trades at ₹885, down 3.6% over the past year, with a market capitalisation of ₹7,984 Cr. Trailing NIFTY 500 for 5 weeks. Prices are weekly closes from Screener data; this page refreshes with each weekly update.
What is Sharda Cropchem Ltd's share price target?
Sector Alpha does not publish broker-style price targets. Our discounted-cash-flow model estimates Sharda Cropchem Ltd's intrinsic value at ₹2,983 per share under base assumptions (bear ₹1,076, bull ₹2,983), against the current price of ₹885 — a 230% margin of safety. The current price already implies roughly 4% annual earnings growth. These are model estimates, not forecasts — treat them as one input alongside the valuation history below, not as a target.
Is Sharda Cropchem Ltd stock overvalued or undervalued?
Sharda Cropchem Ltd trades at a P/E of 11.7× — the 50th percentile of its own 10.3-year trading range (median 17.2×), which is around the middle of its own historical range. Price and profits are moving together. Since Mar 2016, the stock is up 269% and earnings per share are up 289% — the price has tracked the profits, not run ahead of them.
What did Sharda Cropchem Ltd report in its latest quarterly results?
In its most recent reported quarter (Q4 FY26, quarter ended March 2026): Mar 26 sales were ₹2,065 Cr, up 13% on the same quarter last year. Mar 26 profit after tax was ₹319 Cr, up 56% year on year. Figures are from Screener-scraped quarterly filings; the page updates when the next quarter is filed.
Is Sharda Cropchem Ltd growing?
Sales grew 13% last quarter — growth every single quarter for over 2 years. Mar 26 sales were ₹2,065 Cr, up 13% on the same quarter last year.
Are Sharda Cropchem Ltd's profits growing?
Profit exploded 56% — mostly from keeping more of each sale. Mar 26 profit after tax was ₹319 Cr, up 56% year on year.
What are Sharda Cropchem Ltd's operating margins?
Margins are widening — 17% → 24% in a year. In the most recent quarter, of every ₹100 of sales, the company keeps ₹23.6 as operating profit (a year ago it kept ₹16.6).
What is Sharda Cropchem Ltd's long-term growth record?
Revenue grew from ₹790 Cr in FY14 to ₹5,268 Cr in FY26 — a 17.1% compound annual growth rate over 12 years. Profit after tax compounded at 16.3% over the same period (₹111 Cr → ₹681 Cr).
Is Sharda Cropchem Ltd stock in an uptrend?
The price is in a confirmed uptrend — 57 weeks and counting. Sharda Cropchem Ltd is in Stage 2 — advancing, 57 weeks in (confirmed). Stages follow Stan Weinstein's four-phase read of weekly price against the 200-day average: basing (1), advancing (2), topping (3), declining (4).
Is Sharda Cropchem Ltd beating the NIFTY 500?
No — trailing NIFTY 500 for 5 weeks, as of 1 July 2026. Relative strength is measured weekly against the NIFTY 500 (Mansfield RS): a positive reading means the stock has outperformed the index over the trailing window, week after week.
Where is Sharda Cropchem Ltd in its business cycle?
The data reads Sharda Cropchem Ltd as a deep cyclical business currently in its expansion phase — earnings at an all-time high for this company, valuation at the 50th percentile. Profits swing violently in this business — a 91% peak-to-trough profit collapse. That is what “deep cyclical” means: the same company looks brilliant at the top of its cycle and broken at the bottom.
Who owns Sharda Cropchem Ltd — what is the promoter holding?
Promoters hold 74.8%, essentially unchanged. Foreign funds own 4.6%, domestic funds 9.7%. Institutions buying while the story develops is the market’s quiet vote of confidence — they meet management, you don’t. Shareholding is from Screener's quarterly filings data.
Does Sharda Cropchem Ltd have too much debt?
Almost no debt — this company cannot be killed by a bad year. For every ₹100 shareholders have put in (and left in), the company has borrowed ₹0 — total borrowings have shrunk from ₹40.0 Cr to ₹0.0 Cr over the window.
What is the bull case for Sharda Cropchem Ltd?
Profits have nearly tripled in two years, the price has kept pace — no more, no less. Best thing in the data: returns on capital rising (16.0% → 30.0%). Sales grew 13% last quarter — growth every single quarter for over 2 years.
What is the bear case for Sharda Cropchem Ltd — what could break the story?
Two quarters of margins reversing would kill this story. The nearest-term thing to watch: if quarterly growth slips below 6%, the story weakens. This falsification condition is stated up front so the thesis can be checked against incoming quarters, not defended after the fact.
Is Sharda Cropchem Ltd a stock worth studying right now?
Sector Alpha does not publish buy or sell recommendations — this is a research read, not advice. What the data says: worth studying deeper — with eyes open. The numbers lean positive, and the price is roughly fair to the delivery so far. Across the 7-model scorecard the composite research signal is study deeper at 72% confidence. This is machine-written research compiled from Screener data — every number traces to its source — and it is not investment advice. Do your own diligence.